Toxic Shock Syndrome (TSS)

1. Introduction and Definition

Toxic Shock Syndrome (TSS) is an acute, life-threatening, multisystem disorder characterized by high fever, hypotension, diffuse erythroderma (rash), and multiple organ dysfunction. Historically associated with menstruation and high-absorbency tampon use in the late 1970s and early 1980s, TSS is now recognized as a complication of various staphylococcal and streptococcal infections in men, women, and children.

The syndrome is primarily toxin-mediated, caused by superantigens produced by Staphylococcus aureus or Streptococcus pyogenes (Group A Streptococcus ). While Staphylococcal and Streptococcal TSS share pathophysiologic mechanisms, they differ significantly in clinical presentation, epidemiology, and mortality.

2. Etiology and Epidemiology

2.1. Staphylococcal TSS

• Causative Agent: Staphylococcus aureus.
• Toxins: The majority of menstrual TSS cases are caused by Toxic Shock Syndrome Toxin-1 (TSST-1). Non-menstrual cases are associated with TSST-1 or staphylococcal enterotoxins (types A, B, C, D, E, and H).
• Epidemiology:
  • Menstrual TSS: Associated with prolonged use of high-absorbency tampons. The neutral pH and oxygen levels during menstruation facilitate toxin production.
  • Non-Menstrual TSS: Occurs in children and adults associated with focal infections such as abscesses, burns, infected insect bites, surgical wounds, nasal packing, sinusitis, tracheitis, and pneumonia.
  • MRSA vs. MSSA: The majority of S. aureus strains causing TSS are methicillin-susceptible (MSSA), although MRSA-associated TSS occurs.

2.2. Streptococcal TSS (STSS)

• Causative Agent: Streptococcus pyogenes (Group A Streptococcus).
• Toxins: Primarily Streptococcal Pyrogenic Exotoxins (SpeA and SpeC), which act as superantigens.
• Epidemiology: Often associated with severe invasive disease (necrotizing fasciitis, bacteremia, pneumonia). The portal of entry is often the skin (cuts, burns, varicella lesions) or mucous membranes, though in 50% of cases, no portal is identified.

3. Pathogenesis: The Superantigen Concept

The hallmark of TSS pathogenesis is the action of superantigens.

1. Mechanism: Conventional antigens activate only 0.01% to 0.1% of T-cells by binding to the specific antigen-binding groove of the MHC Class II molecule and the T-cell receptor (TCR). Superantigens, however, bind directly to the outer portion of the MHC Class II molecule and the V$\beta$ region of the TCR, bypassing the need for antigen processing.
2. Cytokine Storm: This “short-circuiting” activates a massive number of T-cells (up to 20% of the total T-cell pool). This results in the uncontrolled release of proinflammatory cytokines, particularly Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α).
3. Clinical Effects: These cytokines mediate the clinical features:
   • TNF-$\alpha$ and IL-1: Fever, hypotension, shock, and increased capillary permeability (capillary leak syndrome) leading to hypoalbuminemia and edema.
   • Direct Tissue Injury: Toxin-mediated endothelial damage leads to disseminated intravascular coagulation (DIC) and multiorgan failure.
4. Lack of Antibody Response: In Staphylococcal TSS, a critical risk factor is the host’s lack of neutralizing antibodies against the toxin. Most adults have protective antibodies to TSST-1; those who develop TSS fail to mount an adequate antibody response during the acute illness, predisposing them to recurrence.

4. Clinical Manifestations

4.1. Staphylococcal TSS

The onset is typically abrupt.

• Prodrome: High fever (>38.9°C), chills, myalgia, vomiting, and diarrhea.
• Dermatologic: A diffuse, macular erythroderma (sunburn-like rash) appears within 24 hours. There is often hyperemia of the conjunctival, oropharyngeal, and vaginal mucous membranes. “Strawberry tongue” may be present.
• Hypotension: Systolic BP <90 mm Hg (or <5th percentile for age in children) leading to shock.
• Desquamation: A classic feature occurring 1–2 weeks after onset, typically involving the palms and soles.
• Multisystem Involvement: Confusion/encephalopathy, renal failure (elevated BUN/Creatinine), hepatic dysfunction, and thrombocytopenia are common.

4.2. Streptococcal TSS

Clinically distinct from Staphylococcal TSS in several ways:

• Pain: Severe, localized pain at a site of soft tissue infection is a hallmark early symptom, often preceding physical findings of infection (e.g., in necrotizing fasciitis).
• Focal Infection: Most patients have an identifiable focus, such as cellulitis, fasciitis, or pneumonia.
• Rash: A scarlatiniform or generalized rash occurs but is less common than in Staphylococcal TSS.
• Course: Progression to shock and acute respiratory distress syndrome (ARDS) is often rapid and fulminant.

5. Diagnostic Criteria Diagnostic_criteria

Diagnosis is clinical, supported by laboratory evidence of multisystem involvement and the exclusion of other causes.

5.1. Staphylococcal TSS Case Definition (CDC 2011)

1. Clinical Criteria:

• Fever: Temperature $\ge$ 38.9°C (102.0°F).
• Rash: Diffuse macular erythroderma.
• Desquamation: 1–2 weeks after onset (palms/soles).
• Hypotension: SBP $\le$ 90 mmHg (adults) or <5th percentile (children).
• Multisystem Involvement (3 or more of the following):
  • GI: Vomiting or diarrhea at onset.
  • Muscular: Severe myalgia or CPK >2x upper limit of normal.
  • Mucous Membrane: Vaginal, oropharyngeal, or conjunctival hyperemia.
  • Renal: BUN or Creatinine >2x normal or pyuria without UTI.
  • Hepatic: Bilirubin or Transaminases >2x normal.
  • Hematologic: Platelets <100,000/mm³.
  • CNS: Disorientation or alteration in consciousness without focal signs.

2. Laboratory Criteria:

• Negative serologies for RMSF, Leptospirosis, Measles.
• Blood/CSF cultures negative (except S. aureus blood culture may be positive).

3. Classification:

• Confirmed: Meets laboratory criteria + all 5 clinical criteria (including desquamation, unless patient dies before it occurs).
• Probable: Meets laboratory criteria + 4/5 clinical criteria.

5.2. Streptococcal TSS Case Definition

1. Isolation of Group A Streptococcus:

• From a sterile site (Definite Case).
• From a non-sterile site (Probable Case).

2. Clinical Signs:

• Hypotension PLUS two or more of:
  • Renal impairment.
  • Coagulopathy.
  • Liver involvement.
  • ARDS.
  • Generalized erythematous macular rash (may desquamate).
  • Soft tissue necrosis (necrotizing fasciitis, myositis, gangrene).

6. Differential Diagnosis

• Septic Shock: Bacterial sepsis (Meningococcemia, Gram-negative sepsis).
• Kawasaki Disease: Shares features like fever, rash, mucosal changes, and desquamation. However, Kawasaki disease rarely presents with hypotension/shock, diffuse myalgia, or renal failure (azotemia).
• Multisystem Inflammatory Syndrome in Children (MIS-C): A post-COVID-19 hyperinflammatory syndrome with significant overlap (fever, rash, shock, cardiac dysfunction). Serology for SARS-CoV-2 helps distinguish.
• Drug Reactions: Stevens-Johnson Syndrome (SJS), DRESS syndrome.
• Other Infections: Rocky Mountain Spotted Fever (RMSF), Leptospirosis, Measles, Scarlet Fever.

7. Management

Successful management requires early recognition, aggressive resuscitation, source control, and specific antimicrobial therapy.

7.1. Immediate Stabilization (Resuscitation)

• Fluid Resuscitation: Patients often have profound hypovolemia due to capillary leak. Aggressive fluid replacement with crystalloids is essential to restore perfusion.
• Inotropic Support: Vasopressors (e.g., epinephrine, norepinephrine) are frequently required for refractory hypotension.
• Respiratory Support: Oxygenation and ventilation for patients with ARDS or depressed sensorium.

7.2. Source Control

• Search and Eliminate: Locate the nidus of toxin production.
• Interventions: Remove tampons or nasal packing immediately. Drain abscesses. Debride infected wounds. In cases of necrotizing fasciitis (Strep TSS), prompt and aggressive surgical debridement is critical and life-saving.

7.3. Antimicrobial Therapy

Empiric therapy must cover both S. aureus (including MRSA) and S. pyogenes.

• Protein Synthesis Inhibitor (The “Eagle Effect”):

  • Clindamycin: Clindamycin is a crucial component of therapy. Unlike beta-lactams, its efficacy is not affected by the inoculum size (Eagle effect). More importantly, it is a protein synthesis inhibitor that suppresses the production of bacterial toxins (TSST-1, SpeA) and M-proteins.
  • Dose: Parenteral Clindamycin is recommended as adjunctive therapy.

• Bactericidal Agent:

  • A beta-lactamase-resistant antistaphylococcal agent (e.g., Nafcillin or Oxacillin) or Cefazolin is used for MSSA.
  • Vancomycin is added if MRSA is suspected or prevalent in the community.
  • For Streptococcal TSS, Penicillin G + Clindamycin is the standard regimen.

• Duration: Therapy is typically continued for 10–14 days, depending on the focus of infection.

7.4. Adjunctive Therapies

• Intravenous Immunoglobulin (IVIG):
  • Mechanism: IVIG contains neutralizing antibodies against bacterial superantigens. It may dampen the cytokine storm.
  • Indication: Considered for severe cases of Staphylococcal or Streptococcal TSS refractory to standard therapy.
  • Dose: Regimens vary; high-dose (1–2 g/kg) is often suggested.
• Corticosteroids: Efficacy is debated; not routinely recommended unless there is adrenal insufficiency or specific indication (e.g., refractory shock).

8. Prognosis and Complications

• Mortality:
  • Staphylococcal TSS: Mortality is lower, approximately 3–5% for treated cases.
  • Streptococcal TSS: Mortality is significantly higher, ranging from 30% to 70%, largely due to the aggressive nature of invasive streptococcal disease and rapid onset of shock.
• Recurrence: Recurrent episodes of Staphylococcal TSS can occur, especially in menstrual cases if tampon use is continued, because protective antibodies may not develop after the initial attack.
• Sequelae: Hair and nail loss may occur 1–2 months after recovery. Renal and cardiac functions usually recover, but severe limb ischemia (purpura fulminans) may require amputation.

9. Prevention

• Menstrual TSS: Avoid high-absorbency tampons; change tampons frequently (every 4–8 hours); alternate with pads. History of TSS is a contraindication to future tampon use.
• Wound Care: Proper cleansing and monitoring of wounds, burns, and surgical sites.
• Chemoprophylaxis: Not routinely recommended for contacts of Strep TSS cases unless they are severely immunocompromised or ill.

Summary Table: Staphylococcal vs. Streptococcal TSS

Feature	Staphylococcal TSS	Streptococcal TSS
Pathogen	S. aureus	S. pyogenes (Group A Strep)
Primary Toxin	TSST-1, Enterotoxins	SpeA, SpeC
Portal of Entry	Vagina (tampons), abscess, packing	Skin, throat, deep tissue
Blood Cultures	Often Negative (<5%)	Often Positive (>50%)
Rash	Erythroderma (Sunburn-like)	Less common, may be absent
Local Pain	Rare	Severe, disproportionate
Mortality	< 5%	30–70%
Treatment	Clindamycin + Vancomycin/Nafcillin	Clindamycin + Penicillin